2022 ASCO Voice of China｜A total of 34 Chinese studies were selected in the clinical science forum, oral presentations, and poster discussions!

The annual meeting of the global oncology community - the American Society of Clinical Oncology (ASCO) annual meeting will be held from June 3rd to June 7th, local time
.

The ASCO Annual Meeting is the world's largest, most academically advanced and most authoritative clinical oncology meeting dedicated to cancer prevention, treatment and improved patient management.
advanced treatment methods
.

With the rapid growth of China's clinical research in the field of oncology, China is also playing an increasingly important role in the world's oncology field
.

At this conference, Chinese research was selected into 3 items of Clinical Science Symposium; 15 items of Oral Abstract Session; 17 items of Poster Discussion Session
.

Looking forward to Chinese experts showing their demeanor at the ASCO annual meeting! Clinical Science Forum Gastrointestinal Cancer - Gastroesophageal Cancer, Pancreatic Cancer, Hepatobiliary Cancer 01 Abstract No.
: LBA4011 Title: Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized- controlled, double-blinded, multicenter, and phase III clinical trial.
Presenter: Qin Shukui Unit: Nanjing Jinling Hospital Special Session 02 Abstract No.
: 106 Title: A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).
Reporter: Wang Jing Unit: Hunan Cancer Hospital Hematological Malignancy 03 Abstract No.
: 7008 Title: Autologous CD19-directed CAR T cells produced by novel PrimeCAR manufacture platform exhibit safety, efficacy, and long persistence profiles in relapsed/refractory B-lineage acute leukemia (r/r B-ALL).
Speaker: Li Shiqi Unit: The 9th Joint Logistics Support Force of the Chinese People's Liberation Army 20 Hospital Oral Report Therapeutic Development - Molecular Targeted Drugs and Tumor Biology 01 Abstract No.
: 3000 Title: A phase Ia/Ib study of CBP-1008, Reporter: Qiu Haibo Unit: Sun Yat-sen University Cancer Center Abstract No.
16: 11519 Title: Phase I study of pegylated liposomal doxorubicin in combination with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory sarcoma and other malignant solid tumors.
Reporter: Lu Su British unit: Sun Yat-Sen University Cancer Prevention and Treatment Center Remarks: The rankings are in no particular order.
If there are any omissions, please leave us a message ~ Typesetting: Uni Execution: QuintaEND clinical trial, polite recommendation! 4W+ wheat grains are waiting for you! ▼▼▼Hundreds of medical services, scan the code for consultation! ▼▼▼Famous teacher class, scan the code to enter▼▼▼